The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Open accessAbstract
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma. METHODS: A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival. RESULTS: The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P=0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events. CONCLUSIONS: Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2011, based on promising results from a clinical trial in melanoma patients, the first ICI therapy ipilimumab, an anti-CTLA-4 mAb, has gained FDA approval [98].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While immune checkpoint inhibitors (ICIs) have greatly enhanced clinical outcomes across multiple cancer types,1, 2, 3”
From irAE-GPT: leveraging large language models to identify immune-related adverse events in electronic health records and clinical trial datasets (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“Antibodies against CTLA-4 (ipilimumab) or PD1 (nivolumab) have been shown to induce quick and intense tumor regression in melanoma and NSCLC patients and are currently under clinical investigation in other solid tumors, including CRC [132, 133]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [132]
In the citing paper
“Even though ICIs have shown promising results in adults, there is limited data regarding their safety in children [145].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [145]
In the citing paper
“Ipilimumab (anti-CTLA4) was the first ICT to gain FDA approval in 2011 for the treatment of metastatic melanoma, on the basis of phase III trials demonstrating improvements in overall survival compared with vaccine or chemotherapy (37,38).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [37]
In the citing paper
“Ipilimumab was associated with long-term survival effects (1-year and 2-year survival rate of 45.6% and 23.5%, respectively).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2010
In the citing paper
“Treatment with Ipilimumab was associated with immune-related adverse events (irAEs) in a surprisingly high 60% of patients (Hodi et al., 2010);”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hodi et al., 2010
In the citing paper
“Critically, analogous to what was observed in preclinical studies, the 20% of patients whose tumors were completely cleared maintained their response for the duration of the study, with a median follow-up time of approximately 30 months.”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [32]
In the citing paper
“The combination of ipilimumab and nivolumab has demonstrated enhanced response rates in melanoma, lung cancer, renal cell carcinoma, and mismatch repair deficient colon cancer compared with single agent therapy, although at a cost of increased toxicities (see next section).9–11”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [10]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationCancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Melanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Self-citationManagement of Cutaneous Melanoma
Tsao, H., Atkins, M. B., & Sober, A. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041245 · Cited by 869
Korn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 704
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Lin R, 2008, J Clin Oncol, 26, 497s
Cited by
Sorted by citations
Items 101–200 of 1,189
Non-small cell lung cancer: current treatment and future advances
Zappa, C., & Mousa, S. A. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.07 · Cited by 1,944
The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,924
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802357 · Cited by 1,906
Self-citationRegulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,826
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Self-citationAlsaab, H. O., Sau, S., Alzhrani, R. M., Tatiparti, K., Bhise, K., Kashaw, S. K., & Iyer, A. K. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00561 · Cited by 1,750
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordão, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,718
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
“…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
BackgroundHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,627
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
Togashi, Y., Shitara, K., & Nishikawa, H. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0175-7 · Cited by 1,620
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
Self-citationCD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Schadendorf, D., van Akkooi, A. C. J., Berking, C., Griewank, K., Gutzmer, R., Hauschild, A., Stang, A., Roesch, A., & Ugurel, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31559-9 · Cited by 1,557
Self-citationKwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,505
Self-citationImmunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. M. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,483
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
CD8+ T cell states in human cancer: insights from single-cell analysis
van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,487
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Self-citationMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Lei, X., Lei, Y., Li, J.-K., Du, W.-X., Li, R.-G., Yang, J., Li, J., Li, F., & Tan, H.-B. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.11.009 · Cited by 1,470
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,436
Long, G. V., Stroyakovskiy, D., Gogas, H. J., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,435
Self-citationManagement of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Self-citationRizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,414
A review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,396
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C. B., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,389
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,372
Steeg, P. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.25 · Cited by 1,363
Pitt, J. M., Marabelle, A., Eggermont, A. M. M., Soria, J., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,355
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Eggermont, A. M. M., Chiarion‐Sileni, V., Grob, J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,346
Self-citationThommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,351
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Tawbi, H. A., Forsyth, P. A., Algazi, A. P., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K. D., Lao, C. D., Postow, M. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805453 · Cited by 1,336
Self-citationChaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Self-citationDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,269
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70122-1 · Cited by 1,262
Self-citationSchachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,251
Self-citationActivation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Immune checkpoint inhibitors in melanoma
Carlino, M. S., Larkin, J., & Long, G. V. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01206-x · Cited by 1,235
CTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Cancer immunotherapy: the beginning of the end of cancer?
Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,231
Vaddepally, R. K., Kharel, P., Pandey, R. K., Garje, R., & Chandra, A. B. (2020) · Cancers · doi:10.3390/cancers12030738 · Cited by 1,218
Hargadon, K. M., Johnson, C. E., & Williams, C. J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.06.001 · Cited by 1,211
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,192
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., den Eynde, B. J. V., van der Bruggen, P., & Boon, T. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3670 · Cited by 1,176
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,170
Weller, M., Wick, W., Aldape, K. D., Brada, M., Berger, M. S., Pfister, S. M., Nishikawa, R., Rosenthal, M. A., Wen, P. Y., Stupp, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.17 · Cited by 1,175
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Self-citationRobert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159
Self-citationSafety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Self-citationPatient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Self-citationPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,140
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,136
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Boutros, C., Tarhini, A. A., Routier, É., Lambotte, O., Ladurie, F. L. R., Carbonnel, F., Izzeddine, H., Marabelle, A., Champiat, S., Berdelou, A., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.58 · Cited by 1,100
Self-citationHuman CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena‐Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,098
Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,096
Targeting STAT3 in Cancer Immunotherapy
Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,109
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Self-citationCombinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Self-citationLung cancer: Biology and treatment options
Lemjabbar‐Alaoui, H., Hassan, O. U., Yang, Y., & Buchanan, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.08.002 · Cited by 1,067
Pitt, J. M., Vétizou, M., Daillère, R., Roberti, M. P., Yamazaki, T., Routy, B., Lepage, P., Boneca, I. G., Chamaillard, M., Kroemer, G., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.001 · Cited by 1,060
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,054
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,046
Clinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Self-citationLiu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0654-5 · Cited by 1,039
Self-citationPD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,035
Mlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,033
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
Nishino, M., Ramaiya, N. H., Hatabu, H., & Hodi, F. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.88 · Cited by 1,023
Self-citationLiver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination
Yu, J., Green, M. D., Li, S., Sun, Y., Journey, S. N., Choi, J. E., Rizvi, S. M., Qin, A., Waninger, J. J., Lang, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-1131-x · Cited by 1,021
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,013
Tackling the cancer stem cells — what challenges do they pose?
Pattabiraman, D. R., & Weinberg, R. A. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4253 · Cited by 1,013
Goldberg, S. B., Gettinger, S. N., Mahajan, A. K., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J. V., Vortmeyer, A. O., Jilaveanu, L. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 1,003
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 1,014
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Rotte, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1259-z · Cited by 993
Sangro, B., Gómez-Martín, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu‐Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 989
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
Self-citation
Metadata
- Authors
- Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Angeles Clinic and Research Institute (US)
- Beth Israel Deaconess Medical Center (US)
- St. Mary's Medical Center (US)
- Vanderbilt University Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Colorado Cancer Center (US)
- Institut Gustave Roussy (FR)
- Essen University Hospital (DE)
- University of Mannheim (DE)
- Huntsman Cancer Institute (US)
- Mount Sinai Medical Center (US)
- The Christie Hospital (GB)
- Washington University in St. Louis (US)
- Princess Margaret Cancer Centre (CA)
- University Hospital Southampton NHS Foundation Trust (GB)
- Technical University of Munich (DE)
- Loyola University Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Moffitt Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- ORCID
- Hodi, F. Stephen
- O'Day, Steven J.
- McDermott, David F.
- Sosman, Jeffrey A.
- Haanen, John B.
- Gonzalez, Rene
- Robert, Caroline
- Schadendorf, Dirk
- Hassel, Jessica C.
- Akerley, Wallace
- Lutzky, Jose
- Lorigan, Paul
- Linette, Gerald P.
- Hogg, David
- Ottensmeier, Christian H.
- Peschel, Christian
- Clark, Joseph I.
- Wolchok, Jedd D.
- Weber, Jeffrey S.
- Yellin, Michael J.
- Hoos, Axel
- Urba, Walter J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-19
- Volume
- 363
- Issue
- 8
- Pages
- 711-723
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3549297
- OpenAlex
- W2097995306
- Semantic Scholar
- 51d02526aa36effc4d0eedb5649b37a0fbfc57eb
- Cited by
- 15,155
- References
- 37
- Citations by year
- 2026: 414 · 2025: 584 · 2024: 743 · 2023: 876 · 2022: 880 · 2021: 1154 · 2020: 1165 · 2019: 1106 · 2018: 1215 · 2017: 1290 · 2016: 1262 · 2015: 1265 · 2014: 1017 · 2013: 898 · 2012: 692
- FWCI
- 341.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Syracuse University
- Moffitt Cancer Center
- National Cancer Institute (K24CA097588)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, metastatic melanoma, CTLA-4 blockade, immune checkpoint inhibitors, overall survival, immune-related adverse events, HLA-A*0201, cancer immunotherapy, reinduction therapy, T cell response, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Combined Modality Therapy, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Antigens, CD, Treatment Outcome, Cancer Vaccines, Kaplan-Meier Estimate, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
